New Phase III data demonstrate tiotropium Respimat® improves lung function versus placebo and is well tolerated in asthma patients

Boehringer Ingelheim has announced new data from large scale, Phase III studies showing that once-daily tiotropium delivered via the Respimat® Soft Mist™ Inhaler improved lung function and was well tolerated in patients with varying degrees of asthma severity.1 These data were presented at the American Academy of Allergy, Asthma & Immunology (AAAAI) 2014 annual meeting in San Diego. The first results from the Phase III GraziaTinA-asthma® study demonstrated that tiotropium Respimat® 5 mcg and 2.
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Respiratory / Asthma Source Type: news